Sunesis Pharmaceuticals Inc (SNSS)


Stock Price Forecast

Feb. 24, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sunesis Pharmaceuticals Inc chart...

About the Company

We do not have any company description for Sunesis Pharmaceuticals Inc at the moment.

Please visit http://www.sunesis.com/ for more information about the company.

CEO

Dayton Misfeldt

Exchange

NASDAQ CAPITAL MARKET

Website

http://www.sunesis.com/

$0M

Total Revenue

24

Employees

$74M

Market Capitalization

-3.47

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SNSS News

Buy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financials

6d ago, source:

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Viracta Therapeutics (VIRX – Research Report). The associated ...

Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?

6d ago, source: American Association of Individual Investors

Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...

Ionis stock jumps as MASH drug succeeds in mid-stage trial

on MSN ago, source:

Ionis Pharmaceuticals (NASDAQ:IONS) shares rose in early trading on Wednesday after the company reported positive results ...

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

9h ago, source:

Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular ...

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

19d ago, source: Hosted on MSN

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.99 per share a year ago. These ...

Marinus Pharmaceuticals: Q4 Earnings Snapshot

13d ago, source:

The Radnor, Pennsylvania-based company said it had a loss of 74 cents per share. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...